BACKGROUND Platelet transfusion is of great significance in the treatment of thrombocytopenia caused by myelosuppression during intensive chemotherapy in patients with acute leukemia.In recent years,with platelet tran...BACKGROUND Platelet transfusion is of great significance in the treatment of thrombocytopenia caused by myelosuppression during intensive chemotherapy in patients with acute leukemia.In recent years,with platelet transfusion increasing,ineffective platelet transfusion has become increasingly prominent.Generally speaking,platelet antibodies can be produced after repeated transfusion,thus rendering subsequent platelet transfusion ineffective.We report a case of first platelet transfusion refractoriness(PTR)in a patient with acute myelocytic leukemia(AML).Due to the rarity of such cases in clinical practice,there have been no relevant case reports so far.CASE SUMMARY A 51-year-old female patient attended the hospital due to throat pain and abnormal blood cells for 4 d.Her diagnosis was acute myelocytic leukemia[M2 type Fms related receptor tyrosine kinase 3,Isocitrate Dehydrogenase 1,Nucleophosmin 1,Neuroblastoma RAS viral oncogene homolog(+)high-risk group].She was treated with"IA"(IDA 10 mg day 1-3 and Ara-C 0.2 g day 1-5)chemotherapy.When her condition improved,the patient was discharged from the hospital,instructed to take medicine as prescribed by the doctor after discharge,and returned to the hospital for further chemotherapy on time.CONCLUSION We report a rare case of first platelet transfusion failure in a patient with AML during induction chemotherapy,which may be related to the production of platelet antibodies induced by antibiotics and excessive tumor load.This also suggests that we should consider the influence of antibiotics when the rare situation of first platelet transfusion failure occurs in patients with AML.When platelet antibodies are produced,immunoglobulins can be used to block antibodies,thereby reducing platelet destruction.For patients with PTR,both immune and non-immune factors need to be considered and combined in clinical practice along with individualized treatment to effectively solve the problem.展开更多
Objective:To study the different influence of idarubicin + Arac (IA) therapy and daunorubicin + Arac (DA) therapy on malignant molecule expression of acute myelocytic leukemia. Methods: A total of 56 patients who were...Objective:To study the different influence of idarubicin + Arac (IA) therapy and daunorubicin + Arac (DA) therapy on malignant molecule expression of acute myelocytic leukemia. Methods: A total of 56 patients who were diagnosed with acute myelocytic leukemia in Kashgar Prefecture First People's Hospital between January 2014 and September 2017 were selected as the research subjects and randomly divided into IA group and DA group, and the expression levels of proliferation genes, apoptosis genes and invasion genes in bone marrow tissue were determined after they accepted two courses of different chemotherapy regimens. Results:After two courses of chemotherapy, Daxx, CDX2, MCL1, BCL2, SOX4, S100A6, MMP9, N-cadherin, ICAM-1 and SDF-1 protein expression in bone marrow tissue of IA group were significantly lower than those of DA group whereas SHIP1, Bax and C/EBP protein expression were significantly higher than those of DA group.Conclusion:IA solution for acute myelocytic leukemia can be more effective than DA solution to inhibit the expression of proliferation and invasion genes and increase the expression of apoptosis genes.展开更多
Childhood survivors of acute lymphoblastic leukemia (ALL) are increased risk of several chronic complications, such as second cancers, pulmonary, metabolic complications and cardiovascular disease. Obesity and metabol...Childhood survivors of acute lymphoblastic leukemia (ALL) are increased risk of several chronic complications, such as second cancers, pulmonary, metabolic complications and cardiovascular disease. Obesity and metabolic syndrome is one of the most common treatment related complication in children surviving cancer, which concurs with our nations childhood epidemic [1-3] Recent research has identified the role of genetics in the development of obesity and metabolic syndrome in childhood survivors of ALL. Growth hormone deficiency, Leptin regulation, fat mass obesity (FTO) gene and the insulin resistant ENPP1 variants disorders has been associated adverse effects of chemotherapeutic treatment and the cause of clinical manifestations of metabolic syndrome [4-8]. The illumination of the role of genetic variants can shed insights into obesity within high risk population, as well as, a target to prevent disease.展开更多
Objective To investigate the relationship between cytochrome P4501A1 （CYPIA1） Msp I gene polymorphism and childhood acute leukemia （AL）. Methods Relevant literature was extensively searched and screened by Pubmed ...Objective To investigate the relationship between cytochrome P4501A1 （CYPIA1） Msp I gene polymorphism and childhood acute leukemia （AL）. Methods Relevant literature was extensively searched and screened by Pubmed and Wanfang Database, Chinese Science Journal Database and Chinese Journal Net. Various data consolidation, combined OR values and their 95% CI were tested by RevMan 4.2; Funnel plots were used for the bias analysis. Results Six related literatures were found to meet the requirements. According to heterogeneity results, there was no significant difference in homozygous types（P〉0.05）, while there was significant difference in two others types （P all〈0.05）. For wild CYPIAIMspl homozygous for the reference group, Combined OR of heterozygous mutation, homozygous, heterozygous ＋ homozygous mutation in AL and control groups were 1.18, 0.96, and 1.10 respectively. Subgroup analysis： Z values of CYP1A1Mspl homozygous, heterozygous ＋ homozygous in the acute lymphoblastic leukemia （ALL） and the control group were 0.10 and 0.76 respectively, Z values in non-acute lymphoblastic leukemia and control group were 0.74 and 0.75. Conclusion There is no correlation between CYP1A1Mspl gene polymorphism and the susceptibility of childhood AL.展开更多
Acute Myeloid Leukemia (AML) is a group of genetically diverse hematopoietic malignancies arising from cell progenitors developing in the myeloid pathway or from primitive stem cells. Genetic susceptibility of AML may...Acute Myeloid Leukemia (AML) is a group of genetically diverse hematopoietic malignancies arising from cell progenitors developing in the myeloid pathway or from primitive stem cells. Genetic susceptibility of AML may account for an increased risk of AML due to partial metabolism of or biocativation of carcinogens. Chemical compounds are metabolized by a two-tiered phase detoxifying system. Polymorphisms in these pathways may lead to DNA damage and development of AML. We determined the frequencies of carcinogen metabolism gene polymorphisms (CYP1A1, del{GSTM1} and del{GSTT1}) in a case control-study based on polymorphism analysis. Fifty-eight consecutively AML patients (median age 62 years) and 174 sex and age-matched control group were assessed by a PCR-RFLP assay. There were 51 de novo and 7 secondary AML. CYP1A1*2A and CYP1A1*2C polymorphisms were more frequent in CG than AML p 0.001 and in contrast, CYP1A1*3 and CYP1A1*4 were more frequent in AML than CG p 0.001. There were no differences in del{GSTM1} neither del{GSTT1} between AML and CG (p = 0.999 and p = 0.539). Odds ratio for AML in patients harboring CYP1A1*3 was 2.36 (95% CI 1.2 - 4.5), 2.38 for CYP1A1*4 (95% CI 0.8 - 6.8). Adjusted OR was 2.63 for CYP1A1*3 (95% CI 1.4 - 5.1) and 2.66 for CYP1A1*4 (95% CI 0.9 - 7.8). In the multivariate analysis CYP1A1*3 polymorphism was a risk factor for AML with an OR for 3.99 (95%CI 1.9 - 8.6). To the best of our knowledge this is the first study to show that CYP1A1*3 heterozygous genotypes increase the risk of AML. Our data support that inherited absence of this carcinogen detoxification pathway may be an important determinant of AML.展开更多
BACKGROUND Acute myeloid leukemia is often associated with gene mutation or chromosome abnormality,which is an important factor affecting prognosis.The 5-year survival rate of patients with acute myeloid leukemia with...BACKGROUND Acute myeloid leukemia is often associated with gene mutation or chromosome abnormality,which is an important factor affecting prognosis.The 5-year survival rate of patients with acute myeloid leukemia without hematopoietic stem cell transplantation is low.For patients who only received chemotherapy and whose first remission lasted>5 years,there are few reports of gene spectrum changes between relapse and initial diagnosis.CASE SUMMARY We report a 41-year-old woman who presented to our hospital with complaints of dizziness,poor appetite and wasting.She was diagnosed with acute myelomonocytic leukemia(M4b)with NPM1 mutation and only received chemotherapy.Her first remission lasted>5 years.New genetic variants were detected upon relapse that may have been related to relapse and chemotherapy resistance.CONCLUSION Mutations in WT1(R394fs/A387fs)/PTPN11 T73I/ETV6 S350P and JAK2 W659R may be related to relapse and chemotherapy resistance in acute myeloid leukemia.展开更多
目的探讨成人急性白血病(非M3型)患者的染色体、分子遗传学异常及生存情况。方法选择2019年12月至2022年12月阜阳人民医院血液科收治的148例成人急性白血病患者为研究对象。采用染色体显带分析技术(R显带)及荧光原位杂交等方法检测并分...目的探讨成人急性白血病(非M3型)患者的染色体、分子遗传学异常及生存情况。方法选择2019年12月至2022年12月阜阳人民医院血液科收治的148例成人急性白血病患者为研究对象。采用染色体显带分析技术(R显带)及荧光原位杂交等方法检测并分析患者的染色体核型及分子遗传学特征;通过调阅研究对象病历资料及问卷调查形式收集研究对象一般资料、实验室检查指标及预后情况,采用Kaplan-Meier法绘制生存曲线,采用Log-rank检验进行生存分析。结果148例成人急性白血病患者中,62例为急性淋巴细胞白血病(ALL),以B细胞型急性淋巴细胞白血病居多;86例为急性髓细胞性白血病(AML),亚型以M2、M5较多。141例患者成功行骨髓染色体检查,AML患者中骨髓染色体异常核型比例与ALL患者比较差异无统计学意义(χ^(2)=1.864,P>0.05)。共有143例患者完成了融合基因检查,结果提示81例AML患者中融合基因阳性者28例,其中MLL-R融合基因8例(9.87%);62例ALL患者中融合基因阳性者20例,其中MLL-R融合基因6例(9.68%)。混合谱系白血病基因重排(MLL-R)阳性患者肝脾肿大发生比例显著高于MLL-R阴性患者(χ^(2)=3.645,P<0.05),外周血白细胞计数升高(≥100×109 L-1)比例显著高于MLL-R阴性患者(χ^(2)=7.051,P<0.05),且MLL-R阳性患者骨髓染色体核型异常发生比例显著高于MLL-R阴性患者(χ^(2)=13.961,P<0.05);MLL-R阳性与MLL-R阴性患者在白血病分型、年龄、性别、血小板计数及血红蛋白水平方面比较差异无统计学意义(P>0.05)。ALL组患者中,MLL-R阳性与MLL-R阴性患者的缓解率、复发率及病死率比较差异无统计学意义(P>0.05);AML组患者中,MLL-R阳性与MLL-R阴性患者的缓解率、复发率及病死率比较差异无统计学意义(P>0.05)。接受化学治疗与骨髓干细胞移植治疗的白血病患者的病死率比较差异无统计学意义(P>0.05)。ALL与AML患者1 a无事件生存(EFS)率分别为(41.90±3.20)%、(38.20±2.20)%,ALL与AML患者的1 a EFS率比较差异无统计学意义(χ^(2)=0.512,P>0.05);ALL与AML患者1 a总体生存(OS)率分别为(60.50±4.20)%、(58.20±4.60)%,ALL与AML患者1 a OS率比较差异无统计学意义(χ^(2)=0.175,P>0.05)。MLL-R阳性与MLL-R阴性患者1 a EFS率分别为(34.60±2.70)%、(36.20±3.10)%,MLL-R阳性与MLL-R阴性患者1 a EFS率比较差异无统计学意义(χ^(2)=0.579,P>0.05);MLL-R阳性与MLL-R阴性患者1 a OS率分别为(37.30±4.20)%、(56.60±5.20)%,MLL-R阳性与MLL-R阴性患者1 a OS率比较差异有统计学意义(χ^(2)=4.092,P<0.05)。结论AML及ALL患者在染色体核型异常方面比较无显著差异,在AML及ALL患者中均可见融合基因MLL-R,虽然MLL-R阳性患者更易发生肝脾肿大、染色体核型异常及白细胞计数升高,但MLL-R阳性患者的疗效与阴性患者无明显差异。AML及ALL患者目前治疗方式仍以化学治疗为主,虽然MLL-R阴性患者1 a OS率优于MLL-R阳性患者,但MLL-R阳性与MLL-R阴性患者的1 a EFS率无显著差异。展开更多
基金Supported by Innovation Platform and Talent Program of Hunan Province,No.2021SK4050.
文摘BACKGROUND Platelet transfusion is of great significance in the treatment of thrombocytopenia caused by myelosuppression during intensive chemotherapy in patients with acute leukemia.In recent years,with platelet transfusion increasing,ineffective platelet transfusion has become increasingly prominent.Generally speaking,platelet antibodies can be produced after repeated transfusion,thus rendering subsequent platelet transfusion ineffective.We report a case of first platelet transfusion refractoriness(PTR)in a patient with acute myelocytic leukemia(AML).Due to the rarity of such cases in clinical practice,there have been no relevant case reports so far.CASE SUMMARY A 51-year-old female patient attended the hospital due to throat pain and abnormal blood cells for 4 d.Her diagnosis was acute myelocytic leukemia[M2 type Fms related receptor tyrosine kinase 3,Isocitrate Dehydrogenase 1,Nucleophosmin 1,Neuroblastoma RAS viral oncogene homolog(+)high-risk group].She was treated with"IA"(IDA 10 mg day 1-3 and Ara-C 0.2 g day 1-5)chemotherapy.When her condition improved,the patient was discharged from the hospital,instructed to take medicine as prescribed by the doctor after discharge,and returned to the hospital for further chemotherapy on time.CONCLUSION We report a rare case of first platelet transfusion failure in a patient with AML during induction chemotherapy,which may be related to the production of platelet antibodies induced by antibiotics and excessive tumor load.This also suggests that we should consider the influence of antibiotics when the rare situation of first platelet transfusion failure occurs in patients with AML.When platelet antibodies are produced,immunoglobulins can be used to block antibodies,thereby reducing platelet destruction.For patients with PTR,both immune and non-immune factors need to be considered and combined in clinical practice along with individualized treatment to effectively solve the problem.
文摘Objective:To study the different influence of idarubicin + Arac (IA) therapy and daunorubicin + Arac (DA) therapy on malignant molecule expression of acute myelocytic leukemia. Methods: A total of 56 patients who were diagnosed with acute myelocytic leukemia in Kashgar Prefecture First People's Hospital between January 2014 and September 2017 were selected as the research subjects and randomly divided into IA group and DA group, and the expression levels of proliferation genes, apoptosis genes and invasion genes in bone marrow tissue were determined after they accepted two courses of different chemotherapy regimens. Results:After two courses of chemotherapy, Daxx, CDX2, MCL1, BCL2, SOX4, S100A6, MMP9, N-cadherin, ICAM-1 and SDF-1 protein expression in bone marrow tissue of IA group were significantly lower than those of DA group whereas SHIP1, Bax and C/EBP protein expression were significantly higher than those of DA group.Conclusion:IA solution for acute myelocytic leukemia can be more effective than DA solution to inhibit the expression of proliferation and invasion genes and increase the expression of apoptosis genes.
文摘Childhood survivors of acute lymphoblastic leukemia (ALL) are increased risk of several chronic complications, such as second cancers, pulmonary, metabolic complications and cardiovascular disease. Obesity and metabolic syndrome is one of the most common treatment related complication in children surviving cancer, which concurs with our nations childhood epidemic [1-3] Recent research has identified the role of genetics in the development of obesity and metabolic syndrome in childhood survivors of ALL. Growth hormone deficiency, Leptin regulation, fat mass obesity (FTO) gene and the insulin resistant ENPP1 variants disorders has been associated adverse effects of chemotherapeutic treatment and the cause of clinical manifestations of metabolic syndrome [4-8]. The illumination of the role of genetic variants can shed insights into obesity within high risk population, as well as, a target to prevent disease.
文摘Objective To investigate the relationship between cytochrome P4501A1 （CYPIA1） Msp I gene polymorphism and childhood acute leukemia （AL）. Methods Relevant literature was extensively searched and screened by Pubmed and Wanfang Database, Chinese Science Journal Database and Chinese Journal Net. Various data consolidation, combined OR values and their 95% CI were tested by RevMan 4.2; Funnel plots were used for the bias analysis. Results Six related literatures were found to meet the requirements. According to heterogeneity results, there was no significant difference in homozygous types（P〉0.05）, while there was significant difference in two others types （P all〈0.05）. For wild CYPIAIMspl homozygous for the reference group, Combined OR of heterozygous mutation, homozygous, heterozygous ＋ homozygous mutation in AL and control groups were 1.18, 0.96, and 1.10 respectively. Subgroup analysis： Z values of CYP1A1Mspl homozygous, heterozygous ＋ homozygous in the acute lymphoblastic leukemia （ALL） and the control group were 0.10 and 0.76 respectively, Z values in non-acute lymphoblastic leukemia and control group were 0.74 and 0.75. Conclusion There is no correlation between CYP1A1Mspl gene polymorphism and the susceptibility of childhood AL.
基金supported by the grant providedby CNPq(Conselho Nacional de Desenvolvimento Científico e Tecnológico).The fellowship grant supported by CNPq was Luís Arthur Flores Pelloso,process number 140232/2001-0,period 03/01/2001 to 02/28/2005.
文摘Acute Myeloid Leukemia (AML) is a group of genetically diverse hematopoietic malignancies arising from cell progenitors developing in the myeloid pathway or from primitive stem cells. Genetic susceptibility of AML may account for an increased risk of AML due to partial metabolism of or biocativation of carcinogens. Chemical compounds are metabolized by a two-tiered phase detoxifying system. Polymorphisms in these pathways may lead to DNA damage and development of AML. We determined the frequencies of carcinogen metabolism gene polymorphisms (CYP1A1, del{GSTM1} and del{GSTT1}) in a case control-study based on polymorphism analysis. Fifty-eight consecutively AML patients (median age 62 years) and 174 sex and age-matched control group were assessed by a PCR-RFLP assay. There were 51 de novo and 7 secondary AML. CYP1A1*2A and CYP1A1*2C polymorphisms were more frequent in CG than AML p 0.001 and in contrast, CYP1A1*3 and CYP1A1*4 were more frequent in AML than CG p 0.001. There were no differences in del{GSTM1} neither del{GSTT1} between AML and CG (p = 0.999 and p = 0.539). Odds ratio for AML in patients harboring CYP1A1*3 was 2.36 (95% CI 1.2 - 4.5), 2.38 for CYP1A1*4 (95% CI 0.8 - 6.8). Adjusted OR was 2.63 for CYP1A1*3 (95% CI 1.4 - 5.1) and 2.66 for CYP1A1*4 (95% CI 0.9 - 7.8). In the multivariate analysis CYP1A1*3 polymorphism was a risk factor for AML with an OR for 3.99 (95%CI 1.9 - 8.6). To the best of our knowledge this is the first study to show that CYP1A1*3 heterozygous genotypes increase the risk of AML. Our data support that inherited absence of this carcinogen detoxification pathway may be an important determinant of AML.
基金the Shantou Science and Technology Planning Project of Guangdong Province,No.SFK[2019]79.
文摘BACKGROUND Acute myeloid leukemia is often associated with gene mutation or chromosome abnormality,which is an important factor affecting prognosis.The 5-year survival rate of patients with acute myeloid leukemia without hematopoietic stem cell transplantation is low.For patients who only received chemotherapy and whose first remission lasted>5 years,there are few reports of gene spectrum changes between relapse and initial diagnosis.CASE SUMMARY We report a 41-year-old woman who presented to our hospital with complaints of dizziness,poor appetite and wasting.She was diagnosed with acute myelomonocytic leukemia(M4b)with NPM1 mutation and only received chemotherapy.Her first remission lasted>5 years.New genetic variants were detected upon relapse that may have been related to relapse and chemotherapy resistance.CONCLUSION Mutations in WT1(R394fs/A387fs)/PTPN11 T73I/ETV6 S350P and JAK2 W659R may be related to relapse and chemotherapy resistance in acute myeloid leukemia.
文摘目的探讨成人急性白血病(非M3型)患者的染色体、分子遗传学异常及生存情况。方法选择2019年12月至2022年12月阜阳人民医院血液科收治的148例成人急性白血病患者为研究对象。采用染色体显带分析技术(R显带)及荧光原位杂交等方法检测并分析患者的染色体核型及分子遗传学特征;通过调阅研究对象病历资料及问卷调查形式收集研究对象一般资料、实验室检查指标及预后情况,采用Kaplan-Meier法绘制生存曲线,采用Log-rank检验进行生存分析。结果148例成人急性白血病患者中,62例为急性淋巴细胞白血病(ALL),以B细胞型急性淋巴细胞白血病居多;86例为急性髓细胞性白血病(AML),亚型以M2、M5较多。141例患者成功行骨髓染色体检查,AML患者中骨髓染色体异常核型比例与ALL患者比较差异无统计学意义(χ^(2)=1.864,P>0.05)。共有143例患者完成了融合基因检查,结果提示81例AML患者中融合基因阳性者28例,其中MLL-R融合基因8例(9.87%);62例ALL患者中融合基因阳性者20例,其中MLL-R融合基因6例(9.68%)。混合谱系白血病基因重排(MLL-R)阳性患者肝脾肿大发生比例显著高于MLL-R阴性患者(χ^(2)=3.645,P<0.05),外周血白细胞计数升高(≥100×109 L-1)比例显著高于MLL-R阴性患者(χ^(2)=7.051,P<0.05),且MLL-R阳性患者骨髓染色体核型异常发生比例显著高于MLL-R阴性患者(χ^(2)=13.961,P<0.05);MLL-R阳性与MLL-R阴性患者在白血病分型、年龄、性别、血小板计数及血红蛋白水平方面比较差异无统计学意义(P>0.05)。ALL组患者中,MLL-R阳性与MLL-R阴性患者的缓解率、复发率及病死率比较差异无统计学意义(P>0.05);AML组患者中,MLL-R阳性与MLL-R阴性患者的缓解率、复发率及病死率比较差异无统计学意义(P>0.05)。接受化学治疗与骨髓干细胞移植治疗的白血病患者的病死率比较差异无统计学意义(P>0.05)。ALL与AML患者1 a无事件生存(EFS)率分别为(41.90±3.20)%、(38.20±2.20)%,ALL与AML患者的1 a EFS率比较差异无统计学意义(χ^(2)=0.512,P>0.05);ALL与AML患者1 a总体生存(OS)率分别为(60.50±4.20)%、(58.20±4.60)%,ALL与AML患者1 a OS率比较差异无统计学意义(χ^(2)=0.175,P>0.05)。MLL-R阳性与MLL-R阴性患者1 a EFS率分别为(34.60±2.70)%、(36.20±3.10)%,MLL-R阳性与MLL-R阴性患者1 a EFS率比较差异无统计学意义(χ^(2)=0.579,P>0.05);MLL-R阳性与MLL-R阴性患者1 a OS率分别为(37.30±4.20)%、(56.60±5.20)%,MLL-R阳性与MLL-R阴性患者1 a OS率比较差异有统计学意义(χ^(2)=4.092,P<0.05)。结论AML及ALL患者在染色体核型异常方面比较无显著差异,在AML及ALL患者中均可见融合基因MLL-R,虽然MLL-R阳性患者更易发生肝脾肿大、染色体核型异常及白细胞计数升高,但MLL-R阳性患者的疗效与阴性患者无明显差异。AML及ALL患者目前治疗方式仍以化学治疗为主,虽然MLL-R阴性患者1 a OS率优于MLL-R阳性患者,但MLL-R阳性与MLL-R阴性患者的1 a EFS率无显著差异。
